{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:15:39Z","timestamp":1782494139096,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T00:00:00Z","timestamp":1605225600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007493","name":"University of Colorado Boulder","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007493","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Complementary Therapies in Medicine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ctim.2020.102619","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T08:40:05Z","timestamp":1605861605000},"page":"102619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Experience of migraine, its severity, and perceived efficacy of treatments among cannabis users"],"prefix":"10.1016","volume":"56","author":[{"given":"Laurel P.","family":"Gibson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah N.","family":"Hitchcock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D.","family":"Bryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Cinnamon","family":"Bidwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctim.2020.102619_bib0005","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1001\/jamapsychiatry.2015.1858","article-title":"Prevalence of marijuana use disorders in the United States between 2001\u20132002 and 2012\u20132013","volume":"72","author":"Hasin","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ctim.2020.102619_bib0010","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1080\/00952990.2019.1569668","article-title":"Time trends in US cannabis use and cannabis use disorders overall and by sociodemographic subgroups: a narrative review and new findings","volume":"45","author":"Hasin","year":"2019","journal-title":"Am J Drug Alcohol Abuse"},{"key":"10.1016\/j.ctim.2020.102619_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12954-017-0186-6","article-title":"Psychoactive substances as a last resort\u2014a qualitative study of self-treatment of migraine and cluster headaches","volume":"14","author":"Andersson","year":"2017","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.ctim.2020.102619_bib0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S1474-4422(17)30299-5","article-title":"Global, regional, and national burden of neurological disorders during 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"16","author":"Feigin","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ctim.2020.102619_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/head.12962","article-title":"Cardiovascular events, conditions, and procedures among people with episodic migraine in the US population: results from the American Migraine Prevalence and Prevention (AMPP) study","volume":"57","author":"Buse","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.ctim.2020.102619_bib0030","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-016-0699-5","article-title":"GBD 2015: migraine is the third cause of disability in under 50s","volume":"17","author":"Steiner","year":"2016","journal-title":"J Headache Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0035","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1089\/can.2016.0033","article-title":"The use of cannabis for headache disorders","volume":"2","author":"Lochte","year":"2017","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.ctim.2020.102619_bib0040","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/head.13345","article-title":"Medicinal properties of cannabinoids, terpenes, and flavonoids in cannabis, and benefits in migraine, headache, and pain: an update on current evidence and cannabis science","volume":"58","author":"Baron","year":"2018","journal-title":"Headache"},{"key":"10.1016\/j.ctim.2020.102619_bib0045","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1517\/13543784.10.10.1831","article-title":"Advances in pharmacological treatment of migraine","volume":"10","author":"Diener","year":"2001","journal-title":"Expert Opin Inv Drug"},{"key":"10.1016\/j.ctim.2020.102619_bib0050","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT1B\/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ctim.2020.102619_bib0055","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1586\/14737175.2013.832851","article-title":"Triptans and ergot alkaloids in the acute treatment of migraine: similarities and differences","volume":"13","author":"Tfelt-Hansen","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ctim.2020.102619_bib0060","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/WCO.0000000000000688","article-title":"The endocannabinoid system in migraine: from bench to pharmacy and back","volume":"32","author":"Tassorelli","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ctim.2020.102619_bib0065","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/02791072.2012.684624","article-title":"Cannabis as an adjunct to or substitute for opiates in the treatment of chronic pain","volume":"44","author":"Lucas","year":"2012","journal-title":"J Psychoact Drugs"},{"key":"10.1016\/j.ctim.2020.102619_bib0070","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/dar.12275","article-title":"A safer alternative: cannabis substitution as harm reduction","volume":"34","author":"Lau","year":"2015","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.ctim.2020.102619_bib0075","series-title":"The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research","article-title":"National academies of sciences, engineering, and medicine","year":"2017"},{"key":"10.1016\/j.ctim.2020.102619_bib0080","doi-asserted-by":"crossref","first-page":"172","DOI":"10.3389\/fnins.2018.00172","article-title":"Endocannabinoid system and migraine pain: an update","volume":"12","author":"Greco","year":"2018","journal-title":"Frontiers Neurosci"},{"key":"10.1016\/j.ctim.2020.102619_bib0085","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1468-2982.2009.01924.x","article-title":"Alterations of the endocannabinoid system in an animal model of migraine: evaluation in cerebral areas of rat","volume":"30","author":"Greco","year":"2010","journal-title":"Cephalalgia"},{"key":"10.1016\/j.ctim.2020.102619_bib0090","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2010.03.029","article-title":"The endocannabinoid system and migraine","volume":"224","author":"Greco","year":"2010","journal-title":"Exp Neurol"},{"key":"10.1016\/j.ctim.2020.102619_bib0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1089\/can.2016.0009","article-title":"Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes","volume":"1","author":"Russo","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.ctim.2020.102619_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-007-0391-4","article-title":"Endocannabinoids in platelets of chronic migraine patients and medication-overuse headache patients: relation with serotonin levels","volume":"64","author":"Rossi","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ctim.2020.102619_bib0105","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1038\/sj.npp.1301246","article-title":"Endocannabinoids in chronic migraine: CSF findings suggest a system failure","volume":"32","author":"Sarchielli","year":"2007","journal-title":"Neuropsychopharm"},{"key":"10.1016\/j.ctim.2020.102619_bib0110","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.nbd.2008.01.003","article-title":"Degradation of endocannabinoids in chronic migraine and medication overuse headache","volume":"30","author":"Cupini","year":"2008","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.ctim.2020.102619_bib0115","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/sj.bjp.0705896","article-title":"Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors","volume":"142","author":"Akerman","year":"2004","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.ctim.2020.102619_bib0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1124\/jpet.103.059808","article-title":"Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception","volume":"309","author":"Akerman","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.ctim.2020.102619_bib0125","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1080\/02791072.2011.587700","article-title":"Who are medical marijuana patients? Population characteristics from nine California assessment clinics","volume":"43","author":"Reinarman","year":"2011","journal-title":"J Psychoact Drugs"},{"issue":"34","key":"10.1016\/j.ctim.2020.102619_bib0130","first-page":"141","article-title":"Prevalence of medical marijuana use in California","volume":"2015","author":"Ryan\u2010Ibarra","year":"2012","journal-title":"Drug Alcohol Rev"},{"key":"10.1016\/j.ctim.2020.102619_bib0135","first-page":"989","article-title":"Cannabis as a substitute for prescription drugs\u2013a cross-sectional study","volume":"10","author":"Corroon","year":"2017","journal-title":"J Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0140","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1089\/can.2016.0010","article-title":"Sex differences in cannabis use and effects: a cross-sectional survey of cannabis users","volume":"1","author":"Cuttler","year":"2016","journal-title":"Cannabis Cannabinoid Res"},{"key":"10.1016\/j.ctim.2020.102619_bib0145","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/phar.1673","article-title":"Effects of medical marijuana on migraine headache frequency in an adult population","volume":"36","author":"Rhyne","year":"2016","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ctim.2020.102619_bib0150","article-title":"Short-and long-term effects of cannabis on headache and migraine","author":"Cuttler","year":"2019","journal-title":"J Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0155","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10194-012-0490-1","article-title":"Nabilone for the treatment of medication overuse headache: results of a preliminary doubleblind, active-controlled, randomized trial","volume":"13","author":"Pini","year":"2012","journal-title":"J Headache Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0160","unstructured":"M. Nicolodi, V. Sandoval, A. Terrine, Therapeutic use of cannabinoids \u2010 dose finding, effects, and pilot data of effects in chronic migraine and cluster headache. Abstract presentation at 3rd Congress of the European Academy of Neurology (EAN), Amsterdam, 6\/24\/17."},{"key":"10.1016\/j.ctim.2020.102619_bib0165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fpubh.2019.00099","article-title":"The new runner\u2019s high? Examining relationships between cannabis use and exercise behavior in States with legalized cannabis","volume":"7","author":"YorkWilliams","year":"2019","journal-title":"Front Public Health"},{"key":"10.1016\/j.ctim.2020.102619_bib0170","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0304-3959(83)90143-4","article-title":"Development of the Wisconsin brief pain questionnaire to assess pain in cancer and other diseases","volume":"17","author":"Daut","year":"1983","journal-title":"Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0175","first-page":"S53","article-title":"The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes","volume":"23","author":"Fries","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ctim.2020.102619_bib0180","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1486","article-title":"Validation of a multisubstance online timeline followback assessment","volume":"10","author":"Martin\u2010Willett","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.ctim.2020.102619_bib0185","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1046\/j.1360-0443.2001.967102312.x","article-title":"Marijuana craving questionnaire: development and initial validation of a self\u2010report instrument","volume":"96","author":"Heishman","year":"2001","journal-title":"Addiction"},{"key":"10.1016\/j.ctim.2020.102619_bib0190","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g1416","article-title":"Chronic migraine","volume":"348","author":"Schwedt","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ctim.2020.102619_bib0195","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.3390\/molecules23102478","article-title":"Cannabinoid delivery systems for pain and inflammation treatment","volume":"23","author":"Bruni","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.ctim.2020.102619_bib0200","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1002\/ejp.818","article-title":"Transdermal cannabidiol reduces inflammation and pain\u2010related behaviours in a rat model of arthritis","volume":"20","author":"Hammell","year":"2016","journal-title":"Eur J Pain"},{"key":"10.1016\/j.ctim.2020.102619_bib0205","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.fitote.2010.04.009","article-title":"Comparative topical anti-inflammatory activity of cannabinoids and cannabivarins","volume":"81","author":"Tubaro","year":"2010","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ctim.2020.102619_bib0210","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s11916-011-0188-0","article-title":"ICHD-3: what changes do we need regarding migraine?","volume":"15","author":"Manzoni","year":"2011","journal-title":"Curr Pain Headache R"},{"key":"10.1016\/j.ctim.2020.102619_bib0215","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1001\/jama.296.3.283","article-title":"Migraine and risk of cardiovascular disease in women","volume":"296","author":"Kurth","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ctim.2020.102619_bib0220","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/j.1468-2982.2008.01835.x","article-title":"Agreement of self-reported migraine with ICHD-II criteria in the women\u2019s health study","volume":"29","author":"Sch\u00fcrks","year":"2009","journal-title":"Cephalalgia"}],"container-title":["Complementary Therapies in Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229920318860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0965229920318860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T17:16:48Z","timestamp":1760807808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0965229920318860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":44,"alternative-id":["S0965229920318860"],"URL":"https:\/\/doi.org\/10.1016\/j.ctim.2020.102619","relation":{},"ISSN":["0965-2299"],"issn-type":[{"value":"0965-2299","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Experience of migraine, its severity, and perceived efficacy of treatments among cannabis users","name":"articletitle","label":"Article Title"},{"value":"Complementary Therapies in Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctim.2020.102619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102619"}}